All In Biotech

Drug Trial Radar · NCT07454291

A Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Healthy Participants

A Phase 1, Open-Label Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 in Healthy Participants

Last checked: Nov 19, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

57

Planned (sponsor's estimate)

Start

Apr 28, 2026

Primary completion

Oct 2026

Study completion Oct 2026

Sponsor

Lead sponsor
Endeavor Biomedicines, Inc.Industry
Sponsor type
Industry
First posted
Mar 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 26 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purposes of this study are to: 1. evaluate potential interactions between taladegib (ENV-101) and current standard-of-care (SOC) therapies for idiopathic pulmonary fibrosis (IPF), including nintedanib and pirfenidone, and 2. more fully characterize the pharmacokinetics (PK) of taladegib (i.e., how the body absorbs, distributes, metabolizes and excretes taladegib). This study will enroll 4 cohorts (groups) of participants. Each cohort will experience a different duration of treatment and sequestering (being housed) at the clinical site, followed by a 14-day follow-up period for safety evaluation. The longest duration of treatment for any cohort is 30 days.

Conditions

  • Idiopathic Pulmonary Fibrosis

Interventions

  • taladegibDrug

    low, medium or high dose tablet administered once, or once a day

  • nintedanibDrug

    150 mg capsule administered twice a day

  • pirfenidoneDrug

    One, two or three 267 mg tablets administered three times a day

  • pirfenidoneDrug

    Three 267 mg tablets administered once

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort 1: Taladegib (ENV-101) maximum blood concentration (Cmax) after administration alone and after coadministration with nintedanibTime frame: Day 1 and Day 13
  2. Cohort 1: Time of taladegib maximum blood concentration (Tmax) after administration alone and after coadministration with nintedanibTime frame: Day 1 and Day 13
  3. Cohort 1: Taladegib absorption to time t (AUC[0-t]) after administration alone and after coadministration with nintedanibTime frame: Day 1 and Day 13
  4. Cohort 1: Taladegib total absorption (AUC[0-infinity]) after administration alone and after coadministration with nintedanibTime frame: Day 1 and Day 13
  5. Cohort 1: Taladegib extrapolated total absorption (AUC[extrapolated]) after administration alone and after coadministration with nintedanibTime frame: Day 1 and Day 13
  6. Cohort 1: Taladegib half-life in the blood (T1/2) after administration alone and after coadministration with nintedanibTime frame: Day 1 and Day 13
  7. Cohort 1: Elimination rate constant (K[el]) for taladegib after administration alone and after coadministration with nintedanibTime frame: Day 1 and Day 13
  8. Cohort 1: Apparent oral clearance (CL/F) of taladegib after administration alone and after coadministration with nintedanibTime frame: Day 1 and Day 13
  9. Cohort 1: Apparent volume of distribution (Vz/F) of taladegib after administration alone and after coadministration with nintedanibTime frame: Day 1 and Day 13
  10. Cohort 2: Taladegib maximum blood concentration (Cmax) after administration alone and after coadministration with pirfenidoneTime frame: Day 1 and Day 27
  11. Cohort 2: Time of taladegib maximum blood concentration (Tmax) after administration alone and after coadministration with pirfenidoneTime frame: Day 1 and Day 27
  12. Cohort 2: Taladegib absorption to time t (AUC[0-t]) after administration alone and after coadministration with pirfenidoneTime frame: Day 1 and Day 27
  13. Cohort 2: Taladegib total absorption (AUC[0-infinity]) after administration alone and after coadministration with pirfenidoneTime frame: Day 1 and Day 27
  14. Cohort 2: Taladegib extrapolated total absorption (AUC[extrapolated]) after administration alone and after coadministration with pirfenidoneTime frame: Day 1 and Day 27
  15. Cohort 2: Taladegib half-life in the blood (T1/2) after administration alone and after coadministration with pirfenidoneTime frame: Day 1 and Day 27
  16. Cohort 2: Elimination rate constant (K[el]) for taladegib after administration alone and after coadministration with pirfenidoneTime frame: Day 1 and Day 27
  17. Cohort 2: Apparent oral clearance (CL/F) of taladegib after administration alone and after coadministration with pirfenidoneTime frame: Day 1 and Day 27
  18. Cohort 2: Apparent volume of distribution (Vz/F) of taladegib after administration alone and after coadministration with pirfenidoneTime frame: Day 1 and Day 27
  19. Cohort 3: Pirfenidone maximum blood concentration (Cmax) after administration alone and after coadministration with taladegibTime frame: Day 1 and Day 6
  20. Cohort 3: Time of pirfenidone maximum blood concentration (Tmax) after administration alone and after coadministration with taladegibTime frame: Day 1 and Day 6
  21. Cohort 3: Pirfenidone absorption to time t (AUC[0-t]) after administration alone and after coadministration with taladegibTime frame: Day 1 and Day 6
  22. Cohort 3: Pirfenidone total absorption (AUC[0-infinity]) after administration alone and after coadministration with taladegibTime frame: Day 1 and Day 6
  23. Cohort 3: Pirfenidone extrapolated total absorption (AUC[extrapolated]) after administration alone and after coadministration with taladegibTime frame: Day 1 and Day 6
  24. Cohort 3: Pirfenidone half-life in the blood (T1/2) after administration alone and after coadministration with taladegibTime frame: Day 1 and Day 6
  25. Cohort 3: Elimination rate constant (K[el]) for pirfenidone after administration alone and after coadministration with taladegibTime frame: Day 1 and Day 6
  26. Cohort 3: Apparent oral clearance (CL/F) of pirfenidone after administration alone and after coadministration with taladegibTime frame: Day 1 and Day 6
  27. Cohort 3: Apparent volume of distribution (Vz/F) of pirfenidone after administration alone and after coadministration with taladegibTime frame: Day 1 and Day 6
  28. Cohort 4: Taladegib maximum blood concentration (Cmax) after administration aloneTime frame: Day 1
  29. Cohort 4: Time of taladegib maximum blood concentration (Tmax) after administration aloneTime frame: Day 1
  30. Cohort 4: Taladegib absorption to time t (AUC[0-t]) after administration aloneTime frame: Day 1
  31. Cohort 4: Taladegib total absorption (AUC[0-infinity]) after administration aloneTime frame: Day 1
  32. Cohort 4: Taladegib extrapolated total absorption (AUC[extrapolated]) after administration aloneTime frame: Day 1
  33. Cohort 4: Taladegib half-life in the blood (T1/2) after administration aloneTime frame: Day 1
  34. Cohort 4: Elimination rate constant (K[el]) for taladegib after administration aloneTime frame: Day 1
  35. Cohort 4: Apparent oral clearance (CL/F) of taladegib after administration aloneTime frame: Day 1
  36. Cohort 4: Apparent volume of distribution (Vz/F) of taladegib after administration aloneTime frame: Day 1

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Brisbane, Queensland, Australia · Recruiting

  • Research Site

    Melbourne, Victoria, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.